The E2F4/p130 Repressor Complex Cooperates with Oncogenic ΔNp73α To Inhibit Gene Expression in Human Papillomavirus 38 E6/E7-Transformed Keratinocytes and in Cancer Cells.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
20 04 2023
Historique:
medline: 24 4 2023
pubmed: 9 3 2023
entrez: 8 3 2023
Statut: ppublish

Résumé

Tumor suppressor p53 and its related proteins, p63 and p73, can be synthesized as multiple isoforms lacking part of the N- or C-terminal regions. Specifically, high expression of the ΔNp73α isoform is notoriously associated with various human malignancies characterized by poor prognosis. This isoform is also accumulated by oncogenic viruses, such as Epstein-Barr virus (EBV), as well as genus beta human papillomaviruses (HPV) that appear to be involved in carcinogenesis. To gain additional insight into ΔNp73α mechanisms, we have performed proteomics analyses using human keratinocytes transformed by the E6 and E7 proteins of the beta-HPV type 38 virus as an experimental model (38HK). We find that ΔNp73α associates with the E2F4/p130 repressor complex through a direct interaction with E2F4. This interaction is favored by the N-terminal truncation of p73 characteristic of ΔNp73 isoforms. Moreover, it is independent of the C-terminal splicing status, suggesting that it could represent a general feature of ΔNp73 isoforms (α, β, γ, δ, ε, ζ, θ, η, and η1). We show that the ΔNp73α-E2F4/p130 complex inhibits the expression of specific genes, including genes encoding for negative regulators of proliferation, both in 38HK and in HPV-negative cancer-derived cell lines. Such genes are not inhibited by E2F4/p130 in primary keratinocytes lacking ΔNp73α, indicating that the interaction with ΔNp73α rewires the E2F4 transcriptional program. In conclusion, we have identified and characterized a novel transcriptional regulatory complex with potential implications in oncogenesis.

Identifiants

pubmed: 36883841
doi: 10.1128/msphere.00056-23
pmc: PMC10117100
doi:

Substances chimiques

DNA-Binding Proteins 0
E2F4 protein, human 0
E2F4 Transcription Factor 0
Protein Isoforms 0
Tumor Suppressor Protein p53 0
Crk-Associated Substrate Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0005623

Références

Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cell Death Differ. 2016 Dec;23(12):1930-1940
pubmed: 27716744
Int J Cancer. 2005 May 1;114(5):720-9
pubmed: 15609312
Genome Biol. 2014;15(12):550
pubmed: 25516281
Curr Opin Struct Biol. 2017 Dec;47:1-8
pubmed: 28349863
PLoS Biol. 2020 Jan 16;18(1):e3000599
pubmed: 31945054
Cell Death Differ. 2001 Dec;8(12):1213-23
pubmed: 11753569
Nucleic Acids Res. 2011 May;39(9):3558-73
pubmed: 21247883
Mol Cell. 2007 May 25;26(4):539-51
pubmed: 17531812
Cell Cycle. 2016 Dec;15(23):3183-3190
pubmed: 27753528
Oncogene. 2007 Aug 9;26(36):5169-83
pubmed: 17334395
J Virol. 2019 Mar 21;93(7):
pubmed: 30700603
J Biol Chem. 2002 Aug 9;277(32):29063-8
pubmed: 12034725
Cell Cycle. 2008 Dec;7(23):3737-46
pubmed: 19029828
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Mol Cell. 2004 Jun 4;14(5):625-36
pubmed: 15175157
Cell Death Differ. 2018 Jan;25(1):161-168
pubmed: 29099488
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
BMC Cell Biol. 2013 Aug 06;14:33
pubmed: 23919615
Cancer Res. 2020 Sep 1;80(17):3451-3458
pubmed: 32341036
Cancer Res. 2001 May 15;61(10):4283-6
pubmed: 11358857
Mol Cell Biol. 2011 Jun;31(11):2210-26
pubmed: 21482671
J Mol Biol. 2018 Jun 22;430(13):1829-1838
pubmed: 29733853
PLoS Pathog. 2013 Mar;9(3):e1003186
pubmed: 23516355
Mol Biol Cell. 1996 Jan;7(1):57-70
pubmed: 8741839
Nat Rev Cancer. 2002 Aug;2(8):605-15
pubmed: 12154353
Sci Rep. 2016 Dec 23;6:39382
pubmed: 28008933
Nat Rev Cancer. 2008 Sep;8(9):683-93
pubmed: 19143053
J Struct Biol. 2011 Aug;175(2):178-88
pubmed: 21320604
Nucleic Acids Res. 2012 Jan;40(Database issue):D1144-9
pubmed: 22086960
Genes Dev. 2005 Feb 1;19(3):316-21
pubmed: 15687255
Oncogene. 2006 Mar 2;25(9):1299-310
pubmed: 16247450
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Nat Methods. 2011 Nov 29;8(12):990-2
pubmed: 22127214
Oncogene. 1999 Sep 2;18(35):4993-8
pubmed: 10490834
FASEB J. 2008 Feb;22(2):622-32
pubmed: 17898088
Biochim Biophys Acta. 2014 Jul;1840(7):2171-83
pubmed: 24667034
Nature. 1999 Jun 24;399(6738):806-9
pubmed: 10391249
Cell Cycle. 2013 Jun 15;12(12):1861-7
pubmed: 23708520
Cell Death Differ. 2006 Jun;13(6):962-72
pubmed: 16601753
Nature. 1999 Jun 24;399(6738):809-13
pubmed: 10391250
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4942-4947
pubmed: 28439018
Nucleic Acids Res. 1990 Feb 25;18(4):1068
pubmed: 2156225
Nature. 2015 Dec 3;528(7580):147-51
pubmed: 26550828
Oncogene. 1999 Jul 22;18(29):4171-81
pubmed: 10435630
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17705-10
pubmed: 19815500
Hum Mol Genet. 2014 Dec 20;23(25):6826-37
pubmed: 25104850
Biochem Biophys Res Commun. 2005 Aug 5;333(3):954-60
pubmed: 15975558
Mol Cell Biol. 2014 Jun;34(12):2121-34
pubmed: 24687853
Genes Dev. 2012 Jun 15;26(12):1268-86
pubmed: 22713868
Bio Protoc. 2017 Feb 5;7(3):
pubmed: 28516123
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Virol. 2012 Feb;86(4):2366-70
pubmed: 22171257
Mol Cell Biol. 1995 May;15(5):2682-8
pubmed: 7739548
Cell Cycle. 2007 Aug 1;6(15):1903-13
pubmed: 17671431
Hum Mutat. 2014 Jun;35(6):702-14
pubmed: 24488880
EMBO Rep. 2006 Mar;7(3):334-40
pubmed: 16397624
Nature. 2015 Nov 19;527(7578):384-8
pubmed: 26550823
J Biol Chem. 2002 Nov 8;277(45):43359-68
pubmed: 12213815
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12877-82
pubmed: 20615966
Nat Commun. 2019 Jul 3;10(1):2939
pubmed: 31270324
Nat Biotechnol. 1999 Oct;17(10):1030-2
pubmed: 10504710
Cell Death Dis. 2014 Oct 02;5:e1431
pubmed: 25275592
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6
pubmed: 7690960

Auteurs

Valerio Taverniti (V)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Hanna Krynska (H)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Assunta Venuti (A)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Marie-Laure Straub (ML)

Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Cécilia Sirand (C)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Eugenie Lohmann (E)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Maria Carmen Romero-Medina (MC)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Stefano Moro (S)

Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Alexis Robitaille (A)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Luc Negroni (L)

Proteomics platform, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/INSERM U964/CNRS UMR 7104/Université de Strasbourg, Illkirch, France.

Denise Martinez-Zapien (D)

Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Murielle Masson (M)

Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Massimo Tommasino (M)

IRCCS Istituto Tumori Giovanni Paolo II of Bari, Bari, Italy.

Katia Zanier (K)

Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, Illkirch, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH